Abstract
Non-HodgkinLymphomais aheterogeneous group oflymphoidmalignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.
| Original language | English (US) |
|---|---|
| Title of host publication | Non-Hodgkin Lymphoma |
| Subtitle of host publication | Prognostic Factors and Targets |
| Publisher | Springer New York |
| Pages | 247-266 |
| Number of pages | 20 |
| ISBN (Electronic) | 9781461458517 |
| ISBN (Print) | 9781461458500 |
| DOIs | |
| State | Published - Jan 1 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
}
Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas. / Songdej, Natthapol; Winer, Eric S.
Non-Hodgkin Lymphoma: Prognostic Factors and Targets. Springer New York, 2013. p. 247-266.Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas
AU - Songdej, Natthapol
AU - Winer, Eric S.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Non-HodgkinLymphomais aheterogeneous group oflymphoidmalignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.
AB - Non-HodgkinLymphomais aheterogeneous group oflymphoidmalignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.
UR - http://www.scopus.com/inward/record.url?scp=85028509797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028509797&partnerID=8YFLogxK
U2 - 10.1007/978-1-4614-5851-7_14
DO - 10.1007/978-1-4614-5851-7_14
M3 - Chapter
AN - SCOPUS:85028509797
SN - 9781461458500
SP - 247
EP - 266
BT - Non-Hodgkin Lymphoma
PB - Springer New York
ER -